Coronary artery bypass surgery (CABG) has faced many challenges in its long, winding and debated pathway to adoption as the best therapy for the large majority of patients with triple vessel and left main coronary artery disease (CAD). The slowness to arrive at this important realization was the result, in part, of the nearly 30 years that passed between the publication of the landmark Coronary Artery Surgery Study 1 (CASS) and the Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery (SYN-TAX) trial. 2 Over that time period an explosion in the total number of revascularization procedures has occurred; in particular, percutaneous coronary intervention (PCI). Although the intellectual and data-driven argument is largely settled, the application of these data to clinical practice in the United States and around the globe has lagged behind. The choice between CABG and PCI for select patient populations remains a point of debate, evidenced by the variable application of the Appropriate Use Guidelines to clinical practice. 3 As if this problem was not enough, there has been little concrete evidence of a specific beneficial treatment option for patients with severe left ventricle (LV) dysfunction (LV ejection fraction [LVEF] < 35%) and multivessel CAD. The absence of robust clinical trial data and the fact that previous clinical trials such as the Coronary Artery Surgery Study 1 and the SYNTAX trial 2 excluded patients with severe LV dysfunction has complicated clinical decision making for these patients. The Surgical Treatment for Ischemic Heart Failure (STICH) trial sought to remedy this knowledge gap and to provide treatment insights.
The National Heart, Lung, and Blood Institute-sponsored STICH randomized trial asked a fundamental and longawaited question in patients with severe LV dysfunction (LVEF < 35%) and CAD suitable for revascularization: Is CABG and optimal medical therapy better than optimal medical therapy alone? 4 Between July 2002 and May 2007, 1212 patients with ischemic heart failure were randomized to receive 1 of these 2 treatments. The results of the 10-year STICH trial 5 outcome data and select additional STICH revascularization publications, when woven together, inform us that CABG surgery should be considered the best management strategy for patients with severe LV dysfunction, that there is substantial value in applying a STICH baseline risk prediction strategy to patient care, and that angina as well as preoperative viability and inducible ischemia imaging appear to be less predictive of outcome in this high-risk population.
Ten-Year Outcomes
The STICH trial is the first randomized clinical trial to confirm the benefit of CABG surgery over medical therapy alone in patients with severe LV systolic dysfunction CABG extended median survival by nearly 1.5 years compared with optimal medical therapy alone. CABG compared with medical therapy led to a statistically significant 16% relative risk reduction in death rate and an 8% absolute risk reduction in all-cause mortality. For every 100 patients treated, CABG prevented 8 deaths. In other words, CABG prevented 1 death for every 14 patients treated (Figure 2 ). This beneficial effect was further magnified in the astreated analysis, which was performed to evaluate the effect of crossovers (17% of patients crossed over from medical therapy to CABG). CABG compared with medical therapy led to a 25% relative risk reduction and nearly an 11% absolute risk reduction. In other words, CABG prevented 1 death for every 9 patients who actually received the specific treatment.
In addition, CABG significantly decreased the long-term rates of:
Death from any cause, Death from cardiovascular causes, Death or cardiovascular hospitalization, Death or heart failure hospitalization, Death or repeat revascularization, Death or nonfatal myocardial infarction, or Death or nonfatal stroke.
Despite this knowledge, uncertainty and trepidation remain surrounding which patients with ischemic heart failure should receive CABG surgery and the optimum time in a patient's clinical course to recommend surgery. Clinicians fully understand that patients with ischemic heart failure are challenging, heterogeneous, and complex, and they carry higher perioperative mortality relative to patients with less severe forms of CAD. 6 In the STICH trial, the 30-day operative mortality was 3.6%, remarkably low for a known difficult population. Nevertheless, the 30-day operative mortality was significantly higher than the comparative 30-day postrandomization mortality for medically treated patients. The 10-year data affirm that the 30-day hazard risk favors medical therapy, but after 30 days the risk between therapies is neutral and by 2 years, strongly favors CABG surgery. Understandably, these data leave clinicians contemplating the best option for a specific patient. Does one consider operative mortality more influential in the therapeutic recommendation for a particular patient or does one take the long view recognizing the overwhelming benefit over time of CABG surgery? The STICH investigators recognized this conundrum and in subsequent publications sought to provide additional information to clinicians that could help in making these difficult clinical decisions.
Influence of Angina on Clinical Decisions
Is angina an important prognostic indicator in patients with severe LV dysfunction and CAD? Patients with ischemic heart failure with angina are generally considered to have a worse prognosis and derive a greater benefit from CABG than those patients without angina. 7 The presence of angina denotes ischemic viable myocardium at risk for infarction and as a result, infers greater risk if left untreated. 8 Whereas patients without angina also may have ischemic viable muscle at risk, the absence of angina may suggest less muscle at risk and therefore, a better prognosis in the absence of revascularization or the patient may have scar or denervation and silent ischemia, which might indicate a worse prognosis. 9 Nevertheless, information is sparse regarding the prognostic significance of angina in patients with severe LV dysfunction and CAD.
Jolicoeur and colleagues 10 undertook a substudy analysis of whether angina was associated with a worse prognosis; whether angina identified patients who had a greater survival benefit from CABG, and whether CABG improved angina in patients with LV systolic dysfunction and CAD. The authors concluded that angina did not convey a better or worse prognosis for medically treated patients, or identify patients who received a survival benefit from CABG. 10 Angina relief did improve to a significantly greater extent in those patients who underwent CABG surgery.
The authors' first 2 conclusions are in contradistinction with widely held expert opinions and clinical practice guidelines. 6 A different interpretation of the STICH substudy data provide a few reasons for the dissimilarities between the authors' and other expert opinions. First, the authors interpreted the data among medically treated patients to indicate that the presence or absence of angina was not associated with prognostic benefit. Because the STICH population was overwhelmingly Canadian Cardiovascular Society (CCS) class I or II, these milder forms of angina may have dampened the prognostic effect of angina.
11 Second, the authors interpreted the data to indicate that the interaction on all-cause mortality was not significant between CABG and medical therapy for patients with and without angina. Although the intention-to-treat analysis for CABG did not demonstrate a survival benefit for patients with angina, when crossovers were considered, CABG did confer a prognostic benefit for patients with angina. Among patients without angina, CABG conferred a significant reduction in all-cause mortality compared with medical therapy. Moreover, only 58 patients (7.5%) experienced CCS class III or IV angina and medically treated patients with CCS class III or IV angina did experience higher all-cause mortality compared with patients receiving CABG surgery. Angina severity is widely recognized to be associated with worse outcome.
The interpretation of these STICH data must be considered in the context of the general population of patients with severe LV dysfunction and CAD who exhibit heterogeneous disease gradations, differing degrees of coronary
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Influence of Risk Factors on Clinical Decisions
The STICH investigators asked whether specific baseline clinical risk factors could help physicians treating this heterogeneous and complex group of heart failure patients better identify those patients who would be most likely to benefit from CABG surgery. Panza and colleagues 12 evaluated multiple baseline clinical characteristics selected on the basis of their known prognostic significance. Through univariate and multivariate analyses, the authors arrived at 3 risk factors predictive of outcome. These 3 clinical variables had the greatest likelihood of predicting longterm benefit from CABG: the presence of true 3-vessel CAD (defined as > 50% luminal stenosis), baseline LVEF < 27%, and baseline LV end-systolic volume index (LVESVI) > 79 mL/m 2 . A time-dependent mortality hazard was observed between CABG and medical therapy, demonstrating a higher early risk associated with the CABG operative procedure (30-day mortality) and a midterm survival benefit associated with CABG that became statistically significant at 2 years. The CABG versus medical therapy survival curves crossed after 6 months, indicating the elimination of the time-dependent higher early CABG risk related to the operation (Figure 3) .
This time-related hazard benefit was especially strong in patients undergoing CABG who had 2 or 3 risk factors, but was also true for patients with only 1 risk factor. A highly statistically significant interaction between the number of prognostic factors and the benefit of CABG over medical therapy was seen for all-cause mortality and cardiovascular mortality. Those who benefited the most were patients with true 3-vessel CAD, LVEF < 27%, and those with larger ventricles > 79 mL/m 2 . (LVEF and LVESVI values were selected based on the median values for the STICH population.)
More extensive CAD, worse LV dysfunction, and bigger ventricles intuitively have been believed to be associated with increased operative mortality, instinctively leading to the avoidance of recommending CABG surgery. However, these STICH findings do not confirm that view. In medically treated patients, these risk factors predicted the likelihood of death. There was a significantly higher mortality in medically treated patients with 2 or 3 prognostic factors compared with medically treated patients with 0 to 1 factor (P <.001). On the other hand, higher mortality associated with prognostic risk factors was not observed among patients randomized to receive CABG. The benefit of CABG was irrespective of risk factors. In other words, there 5 was no difference in mortality for CABG treated patients with 2 to 3 prognostic factors compared with CABGtreated patients with 0 to 1 factor. The 30-day mortality for CABG among patients with 2 to 3 prognostic factors (3.57%) was identical to those patients with 0 to 1 prognostic factor (3.65%). The long-held belief that prognostic risk factors such as these in patients with severe LV dysfunction result in a higher-risk operation is not supported by these data and should confirm the rationale for offering CABG surgery to patients with severe LV dysfunction. The risk of CABG surgery was offset by the even higher mortality of medical therapy over the 10 years of the study in patients with severe ischemic LV dysfunction.
Influence of Viability and Inducible Ischemia on Clinical Decisions
Because patients with mild to moderate LV dysfunction and CAD may see substantial improvement in LV function after CABG, myocardial viability has been proposed as a discriminating therapeutic strategy for patients with severe LV dysfunction. [13] [14] [15] The STICH investigators sought to answer whether the performance of preoperative viability or ischemia imaging could further enhance risk assessment between medical therapy and CABG.
Bonow and colleagues 16 found no significant interaction between myocardial viability and the treatment received for the end points of death from any cause, death from cardiovascular causes, and the composite of allcause death plus cardiovascular hospitalization. This conclusion was true whether patients were evaluated according to the intention-to-treat analysis or to the astreated analysis. The authors concluded that in patients with CAD and severe LV dysfunction, assessment of myocardial viability did not identify patients who had the greatest survival benefit from adding CABG to optimal medical therapy.
Because these results were identified in patients with severe LV dysfunction and not mild or moderate LV dysfunction, they likely describe a novel finding. But what are the implications of these findings, especially because they run countercurrent to practice patterns that have been employed to give clinicians confidence in proceeding with coronary revascularization? First, viability was not mandated as a STICH inclusion criterion, it was assessed only in those patients in whom investigators at the clinical site believed it was an important preoperative study. Thus, the viability analysis was conducted only on a subset of the STICH population and may not represent the population as a whole. Second, whereas these findings discount the predictive utility of viability assessment in the STICH patient group, they do not indicate that myocardial viability is of no pathophysiologic importance. In fact, the authors admit that other variables, such as LV volume and LVEF, carry more prognostic acumen and that these variables are notably determined by the extent of viable myocardium. In other words, in patients with severe LV dysfunction, viability may have lost its fidelity to predict outcome, which is retained by LV size and function, and yet, these latter 2 variables are mechanistically influenced by viability. Therefore, one should not ignore viability in the preoperative assessment of an individual patient. If anything, it may provide confidence to a clinician to recommend surgery, whereas its absence should not dissuade a clinician from such a recommendation based on these data from STICH confirming benefit from CABG in the absence of viability. If viability could not reliably identify patients best suited for CABG surgery, could inducible ischemia be used to help predict benefit? Patients with inducible ischemia are known to be at greater risk of death when managed medically. [17] [18] [19] Dysfunctional and ischemic muscle is viable and its function would be expected to improve following revascularization. Panza and colleagues 20 questioned whether the benefit of CABG seen in STICH, although not reliably identified with viability testing, could be linked to ischemic myocardium that might be identified on stress testing, permitting enhanced patient selection of patients for revascularization surgery. These authors were unable to identify any interaction between treatment allocation and the presence or absence of inducible ischemia for the end points of death from any cause, death from cardiovascular causes, and for the composite of all-cause death plus cardiovascular hospitalization. Similar findings were observed in the intention-to-treat and the as-treated analyses.
These results, taken together with the viability results, suggest that the known therapeutic benefit of CABG over medical therapy in STICH patients with severe LV dysfunction is not limited to patients with inducible myocardial ischemia or with evidence of myocardial viability. These observations stand in contrast to current management strategies for patients with less severe forms of CAD where the results of stress testing demonstrating inducible ischemia and the presence of viability on perfusion studies are used to select patients who would be expected to benefit from CABG surgery. [13] [14] [15] [16] [17] [18] [19] The findings of Bonow and colleagues 16 and Panza and colleagues 12 indicate that once severe LV dysfunction and severe LV remodeling have occurred, the prognostic benefit of inducible ischemia and viability are lost in comparison to patients with milder degrees of LV dysfunction and remodeling.
Weaving a Logical Explanation for the Benefit of CABG How might we explain these differences between patients with milder forms of LV dysfunction and those with severe dysfunction with respect to the value of preoperative viability and/or perfusion studies? In part, these differences could be explained on the basis of post hoc analyses performed in a subset of patients who happened to have had these studies performed at the discretion of the study site investigators and therefore carry less significance. Or perhaps, these data should be accepted as discerning and one should consider that the benefit of CABG in patients with severe LV dysfunction is related to the prevention of future cardiovascular events that are not linked in a causal mechanistic manner to viability or ischemia. Evidence to support this consideration comes from the mode-of-death results in STICH patients. Carson and colleagues 21 found that patients undergoing CABG surgery had a significantly reduced risk of sudden death, pump failure, and deaths from myocardial infarction compared with patients treated with medical therapy (Figure 4 ). These cardiovascular events are undeniably the consequence of critically diseased coronary arteries. One could postulate from these data that CABG surgery protected patients from future fatal events that occurred from progressively worsening coronary vessels not present or less severe at the time of initial stress testing and myocardial viability imaging.
Is PCI a Substitute for CABG?
Finally, some will ask if PCI might have the same benefit as CABG surgery for patients with ischemic heart failure. Notwithstanding the intellectual leap of evidence necessary for this conjecture to be true when PCI did not demonstrate equivalence to CABG in SYNTAX-it would be unlikely for PCI to convey benefit in patients with severe LV dysfunction-this conjecture deserves attention. Two recent studies provide evidence of the definite benefit of CABG surgery over PCI in patients with multivessel disease and severe LV dysfunction. Nagendran and colleagues 22 performed a propensity-matched study of CABG versus PCI in patients with CAD, diabetes mellitus, and severe LV dysfunction (LVEF < 35%). PCI compared with CABG was associated with a statistically significant higher risk of death, myocardial infarction, major adverse cardiac and cerebrovascular events, and repeat revascularization. In addition, Iribarne and colleagues 23 from the Northern New England Cardiovascular Disease Study Group conducted a retrospective analysis among 7 New England medical centers that prospectively maintained a clinical registry. The propensity-matched study cohort included 955 CABG and 718 PCI patients with LVEF 35% and 2-or 3-vessel disease. CABG was associated with a statistically significant improved long-term survival when compared with PCI.
Clinical Recommendations
Taken in aggregate, the STICH data inform clinicians that the management of patients with severe LV dysfunction and CAD has evolved to strongly advocate for CABG surgery as the primary therapy. Important recent changes in medical therapies for ischemic heart failure, including medications, use of cardiac resynchronization therapy, and mechanical circulatory support have complemented and often extended the indications for CABG surgery in this complex group of patients. The influence of these changes, although significant, does not alter the fundamental benefit of CABG surgery. In essence, patients with advanced ischemic heart failure receive a greater survival benefit from CABG than optimal medical therapy. A time-dependent survival advantage was observed for CABG in STICH and the benefit was magnified for patients in whom 1 or more specific prognostic risk factors were present. It is important to recognize that the thresholds for LVEF and LESVI in STICH risk factor prognostication were determined on the basis of the median values for the STICH population (median LVEF 27%; median LVESVI 79 mL/m 2 ). Clinicians should use their own best clinical judgment in determining their tolerance for any deviation from these thresholds. Imaging studies and provocative testing are of limited value compared with geometric (ie, LVESVI) and functional (ie, LVEF) parameters in predicting the survival benefit of coronary revascularization in patients with ischemic heart failure. However, in patients with 0 risk factors, evidence of viability or ischemia or the presence of angina may be helpful in providing confidence to clinicians to extend a recommendation for CABG surgery.
CONCLUSIONS
The STICH trial has reinforced our understanding that patients with severe LV dysfunction and ischemic heart failure behave differently than do patients with less severe forms of CAD. Severe LV dysfunction should prompt an evaluation of the presence, extent, and severity of angiographic CAD. Among patients with ischemic heart failure, CABG surgery should be strongly encouraged to improve survival and to reduce the risk of future cardiovascular events.
